356 related articles for article (PubMed ID: 30404927)
41. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.
Ito D; Fujimoto K; Mori T; Kami K; Koizumi M; Toyoda E; Kawaguchi Y; Doi R
Int J Cancer; 2006 May; 118(9):2337-43. PubMed ID: 16331623
[TBL] [Abstract][Full Text] [Related]
42. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.
Sharma N; Nanta R; Sharma J; Gunewardena S; Singh KP; Shankar S; Srivastava RK
Oncotarget; 2015 Oct; 6(31):32039-60. PubMed ID: 26451606
[TBL] [Abstract][Full Text] [Related]
43. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
44. Antitumor effect of Kanglaite® injection in human pancreatic cancer xenografts.
Liu Y; Zhang W; Wang XJ; Liu S
BMC Complement Altern Med; 2014 Jul; 14():228. PubMed ID: 25005526
[TBL] [Abstract][Full Text] [Related]
45. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism.
Zhu H; Xiao Y; Guo H; Guo Y; Huang Y; Shan Y; Bai Y; Lin X; Lu H
Aging (Albany NY); 2021 Dec; 13(23):25089-25105. PubMed ID: 34863080
[TBL] [Abstract][Full Text] [Related]
46. Antiproliferative Effects of Matricine in Gemcitabine-Resistant Human Pancreatic Carcinoma Cells Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT Signalling Pathway.
Fang K; Wang L; Chen L; Liu T; Fang Z
Med Sci Monit; 2019 Apr; 25():2943-2949. PubMed ID: 31005960
[TBL] [Abstract][Full Text] [Related]
47. Saikosaponin d modulates the polarization of tumor-associated macrophages by deactivating the PI3K/AKT/mTOR pathway in murine models of pancreatic cancer.
Xu X; Cui L; Zhang L; Yang L; Zhuo Y; Li C
Int Immunopharmacol; 2023 Sep; 122():110579. PubMed ID: 37433245
[TBL] [Abstract][Full Text] [Related]
48. Ursolic Acid Induces Apoptosis of Prostate Cancer Cells via the PI3K/Akt/mTOR Pathway.
Meng Y; Lin ZM; Ge N; Zhang DL; Huang J; Kong F
Am J Chin Med; 2015; 43(7):1471-86. PubMed ID: 26503559
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
50. Targeting mTOR dependency in pancreatic cancer.
Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
[TBL] [Abstract][Full Text] [Related]
51. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer.
De Santis MC; Gozzelino L; Margaria JP; Costamagna A; Ratto E; Gulluni F; Di Gregorio E; Mina E; Lorito N; Bacci M; Lattanzio R; Sala G; Cappello P; Novelli F; Giovannetti E; Vicentini C; Andreani S; Delfino P; Corbo V; Scarpa A; Porporato PE; Morandi A; Hirsch E; Martini M
Gut; 2023 Feb; 72(2):360-371. PubMed ID: 35623884
[TBL] [Abstract][Full Text] [Related]
52. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
53. PI3K/AKT/mTOR signaling is involved in (-)-epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells.
Liu S; Wang XJ; Liu Y; Cui YF
Am J Chin Med; 2013; 41(3):629-42. PubMed ID: 23711146
[TBL] [Abstract][Full Text] [Related]
54. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
55. BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity.
Saiyin H; Na N; Han X; Fang Y; Wu Y; Lou W; Yang X
Oncotarget; 2017 Jul; 8(27):44669-44681. PubMed ID: 28591720
[TBL] [Abstract][Full Text] [Related]
56. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
57. Luteoloside induces G
Zhou M; Shen S; Zhao X; Gong X
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):263-269. PubMed ID: 29024631
[TBL] [Abstract][Full Text] [Related]
58. LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.
Zhang H; Pan YZ; Cheung M; Cao M; Yu C; Chen L; Zhan L; He ZW; Sun CY
Cell Death Dis; 2019 Mar; 10(3):230. PubMed ID: 30850586
[TBL] [Abstract][Full Text] [Related]
59. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS
Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
[TBL] [Abstract][Full Text] [Related]
60. Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling.
Wang K; Huang W; Sang X; Wu X; Shan Q; Tang D; Xu X; Cao G
Phytomedicine; 2020 Mar; 68():153191. PubMed ID: 32135457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
